Cosmos Health Sets 2029 Growth Roadmap, Targets $200M Revenue

Key Facts

1The company targets $200.6 million in revenue by 2029 with a 32% compound annual growth rate.

2The company expects to transition to profitability in 2027 and reach a net income of $31 million by 2029.

3The company plans to repay all convertible notes and expects cash to exceed total debt levels by 2027.

In a move reflecting its expansion ambitions within the healthcare sector, Cosmos Health has announced its strategic financial targets for the 2026-2029 period. The company aims to achieve revenues of $200.6 million by 2029, supported by a compound annual growth rate (CAGR) of 32%. The guidance also includes a pivotal shift toward profitability by 2027, targeting a net income of $31 million by the end of the forecast period.

This strategic direction follows the company's strongest historical financial performance in 2025, as management seeks to leverage high-margin proprietary segments and AI-driven efficiencies. Compared to other micro-cap healthcare peers, Cosmos Health is focusing on optimizing its capital structure; it plans to repay all convertible notes to ensure cash levels exceed total debt by 2027. Per market data, such long-term financial guidance is typically aimed at bolstering investor confidence in cash flow sustainability.

Operationally, traders are monitoring COSM stock levels, which are directly impacted by the company's ability to execute its debt reduction plans. Looking at the economic calendar, investors are awaiting the FOMC Minutes on May 20, 2026, which could influence financing costs for growth-stage companies. Focus remains on upcoming quarterly reports to verify that actual results align with the targeted growth trajectory.